


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

### AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Currently amended) A compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

$W^1$  is nitrogen or CH,  $W^2$  is nitrogen or  $C-(U)_pR^U$ , and  $W^3$  is nitrogen or  $C-(V)_qR^V$ ;

p and q are each independently 0 or 1;

$R^U$  and  $R^V$  are each independently R or  $Ar^1$ ;

U and V are each independently a bond or a  $C_{1-6}$  alkylidene chain, wherein up to two

methylene units of the chain are optionally and independently replaced by CO,  $CO_2$ ,

COCO, CONR, OCONR, NRNR, NRNRCO, NRCO,  $NRCO_2$ , NRCONR, SO,  $SO_2$ ,

$NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR;

each occurrence of R is independently hydrogen or an optionally substituted  $C_1-C_4$  aliphatic,

or two R bound to the same nitrogen atom are optionally taken together with the

nitrogen atom to form a 3-7 membered saturated, partially unsaturated, or fully

unsaturated ring having 0-2 additional heteroatoms independently selected from

nitrogen, oxygen, or sulfur;

$Ar^1$  is a 5-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring

having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or


an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring

system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

sulfur; wherein  $Ar^1$  is optionally substituted with  $m$  independent occurrences of  $Z-R^5$ ; wherein  $m$  is 0-5,  $Z$  is a bond or is a  $C_1-C_6$  alkylidene chain wherein up to two methylene units of  $Z$  are optionally replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR, NRNRCO, NRCO,  $NRCO_2$ , NRCONR, SO,  $SO_2$ ,  $NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR; and each occurrence of  $R^5$  is independently hydrogen, an optionally substituted aliphatic, heteroaliphatic, aryl or heteroaryl group, halogen,  $NO_2$ , CN, OR, SR,  $N(R)_2$ , NRCOR,  $NRCON(R)_2$ ,  $NRCO_2R$ , COR,  $CO_2R$ , OCOR,  $CON(R)_2$ ,  $OCON(R)_2$ , SOR,  $SO_2R$ ,  $SO_2N(R)_2$ ,  $NRSO_2R$ ,  $NRSO_2N(R)_2$ , COCOR, or  $COCH_2COR$ ;

$R^1$  and  $R^2$  are taken together and fused to ring B to form a bicyclic heterocyclic moiety selected from one of the following formulae (a) through (f):



Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936



wherein each occurrence of  $R^X$  is independently hydrogen, QR, or  $Q_nAr^1$ ; n is zero or one;  
 and Q is an optionally substituted  $C_{1-4}$  alkylidene chain wherein one methylene unit of Q  
 is optionally replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR, NRNRCO, NRCO,  
 NRCO<sub>2</sub>, NRCONR, SO,  $SO_2$ ,  $NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR;

$R^3$  is hydrogen, halogen, QR,  $Q_nCN$ ,  $Q_nNO_2$ , or  $Q_nAr^1$ ; and

$R^4$  is  $Ar^1$ , or T- $Ar^1$ ;

wherein T is a  $C_{1-2}$  alkylidene chain wherein one methylene unit of T is optionally  
 replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO<sub>2</sub>,  
 NRCONR, SO,  $SO_2$ ,  $NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR.

2. (Currently amended) The compound of claim 1, wherein  $R^1$  and  $R^2$  taken together  
 represent heterocycle-i form the heterocyclic moiety of formula (a) and  $R^X$  is hydrogen or  
 optionally substituted  $C_{1-6}$  aliphatic.

3. (Original) The compound of claim 1, wherein  $R^X$  is hydrogen, methyl, ethyl, propyl,  
 n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl,  $C_{1-6}$ alkyl substituted with  $N(R)_2$ ,  
 or  $C_{1-6}$ alkyl substituted with  $Ar^1$ .

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

4. (Original) The compound of claim 1, wherein  $R^x$  is hydrogen, methyl, or  $C_{1-7}$ alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidiny, or piperazinyl.
5. (Original) The compound of claim 1, wherein  $R^3$  is hydrogen, halogen, QR or  $QAr^1$ , wherein Q is a  $C_{1-3}$  alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and  $Ar^1$  is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
6. (Original) The compound of claim 1, wherein  $R^3$  is hydrogen, OH,  $OCH_3$ ,  $OCH_2CH_3$ ,  $NHCOMe$ ,  $NH_2$ ,  $NH(C_{1-4}$  aliphatic),  $N(C_{1-4}$  aliphatic) $_2$ ,  $O(CH_2)_2$ morpholin-4-yl,  $O(CH_2)_2NH_2$ ,  $O(CH_2)_2NH(C_{1-4}$  aliphatic),  $O(CH_2)_2N(C_{1-4}$  aliphatic) $_2$ , Br, Cl, or F.
7. (Original) The compound of claim 1, wherein  $R^3$  is hydrogen.
8. (Original) The compound of claim 1, wherein  $R^4$  is a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogen atoms, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each ring is optionally substituted.
9. (Original) The compound of claim 1, wherein  $R^4$  is optionally substituted phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl.
10. (Original) The compound of claim 1, wherein  $R^4$  is an optionally substituted phenyl group.

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936



11. (Original) The compound of claim 8, wherein each occurrence of Z is independently a bond or a C<sub>1-4</sub> alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, -SO<sub>2</sub>-, or -NH-; and each occurrence of R<sup>5</sup> is independently hydrogen, C<sub>1-6</sub> aliphatic, halogen, NO<sub>2</sub>, OR, N(R)<sub>2</sub>, or optionally substituted phenyl, pyridyl, or pyrimidinyl.

12. (Currently amended) The compound of claim 8, wherein each occurrence of ZR<sup>4</sup> is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, CF<sub>3</sub>, NH<sub>2</sub>, phenyl, benzyl, benzyloxy, OH, ~~methylene-dioxy~~ methylenedioxy, SO<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, CO<sub>2</sub>Me, phenoxy, O-pyridinyl, SO<sub>2</sub>phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, ~~aminophenyl~~, phenyl, chloro-fluoro-phenyl, dimethylaminophenyl, CF<sub>3</sub>-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, and fluorophenoxy.

13. (Original) The compound of claim 1, wherein (U)<sub>p</sub>R<sup>U</sup> and (V)<sub>q</sub>R<sup>V</sup> are each independently hydrogen, halogen, NO<sub>2</sub>, CN, OR, SR or N(R)<sub>2</sub>, or C<sub>1-4</sub>aliphatic optionally substituted with oxo, OR, SR, N(R)<sub>2</sub>, halogen, NO<sub>2</sub> or CN.

14. (Original) The compound of claim 1, wherein (U)<sub>p</sub>R<sup>U</sup> and (V)<sub>q</sub>R<sup>V</sup> are each independently hydrogen, Me, OH, or OMe.


15. (Original) The compound of claim 1, wherein W<sup>1</sup> is N or CH and compounds have the structure of Formula Ia or Ib:




Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

or a pharmaceutically acceptable salt thereof.

16. (Currently amended) The compound of claim [[1]] 15, wherein  $R^4$  is an optionally substituted phenyl group and compounds have the structure of Formula IIa or IIb:




IIa




IIb

or a pharmaceutically acceptable salt thereof.

17. (Currently amended) The compound of claim [[1]] 16, wherein  $R^3$  is hydrogen, and compounds have the general structure of Formula IIIa or IIIb:



IIIa




IIIb


or a pharmaceutically acceptable salt thereof.

18. (Currently amended) The compound of claim [[1]] 16, wherein  $R^3$  is hydrogen, and  $R^1$  and  $R^2$  taken together represent the heterocycle 4 form the heterocyclic moiety of formula (a) and compounds have the general structure of Formula IVa or IVb:

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936



IVa



IVb

or a pharmaceutically acceptable salt thereof.

19. (Currently amended) The compound of claim 15 of any one of claims 15, 16, 17 or 18, wherein

i)  $R^1$  and  $R^2$  taken together represent the heterocycle depicted above form the heterocyclic moiety of formula (a); where  $R^X$  is defined according to one of the following groups:

[[a.]] (a) hydrogen or optionally substituted  $C_{1-6}$  aliphatic;

[[b.]] (b) hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl,  $C_{1-6}$  alkyl substituted with  $N(R)_2$ , or  $C_{1-6}$  alkyl substituted with  $Ar^1$ ; or

[[c.]] (c) hydrogen, methyl, or  $C_{1-2}$  alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidiny, or piperazinyl.

ii)  $R^2$  is defined according to one of the following groups:

[[a.]] (a) hydrogen, halogen, QR or  $QAr^1$ , wherein Q is a  $C_{1-3}$  alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and  $Ar^1$  is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

[[b.]] (b) hydrogen, OH,  $OCH_3$ ,  $OCH_2CH_3$ ,  $NHCOMe$ ,  $NH_2$ ,  $NH(C_{1-4} \text{ aliphatic})$ ,  $N(C_{1-4} \text{ aliphatic})_2$ ,  $O(CH_2)_2\text{morpholin-4-yl}$ ,  $O(CH_2)_2NH_2$ ,

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

$O(CH_2)_2NH(C_{1-4} \text{ aliphatic})$ ,  $O(CH_2)_2N(C_{1-4} \text{ aliphatic})_2$ , bromo, chloro, or fluoro; or

[[c.]] (c) hydrogen;

iii)  $R^4$  is defined according to one of the following groups:

[[a.]] (a) a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogens, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each said ring is optionally substituted with  $(ZR^3)_m$ ;

[[b.]] (b) an optionally substituted ring selected from phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl, wherein said ring is optionally substituted with  $(ZR^3)_m$ ; or

[[c.]] (c) an optionally substituted phenyl group, wherein said phenyl group is optionally substituted with  $(ZR^3)_m$ ;

iv)  $W^1$ ,  $W^2$  and  $W^3$  are defined according to one of the following groups:

[[a.]] (a)  $W^1$  is nitrogen or CH,  $W^2$  is nitrogen or  $C-(U)_pR^U$ , and  $W^3$  is nitrogen or  $C-(V)_qR^V$ ;

[[b.]] (b)  $W^1$  is nitrogen or CH,  $W^2$  is  $C-(U)_pR^U$ , and  $W^3$  is  $C-(V)_qR^V$ ; or

[[c.]] (c)  $W^1$  is nitrogen or CH and  $W^2$  and  $W^3$  are each CH; and

v)  $(U)_pR^U$  and  $(V)_qR^V$  groups are defined according to one of the following groups:

[[a.]] (a) hydrogen, halogen,  $NO_2$ , CN, OR, SR or  $N(R)_2$ , or  $C_{1-4}$  aliphatic optionally substituted with oxo, OR, SR,  $N(R)_2$ , halogen,  $NO_2$  or CN;

[[b.]] (b) hydrogen, Me, OH, OMe or  $N(R)_2$ ; or

[[c.]] (c) both  $(U)_pR^U$  and  $(V)_qR^V$  are hydrogen.

20. (Currently amended) The compound of any one of claims 16, 17, 18 or 19 claim 19, wherein each occurrence of Z is independently a bond or a  $C_{1-4}$  alkylidene chain wherein one


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

methylene unit of Z is optionally replaced by -O-, -S-, -SO<sub>2</sub>-, or -NH-; and each occurrence of R<sup>5</sup> is independently hydrogen, C<sub>1-6</sub> aliphatic, halogen, NO<sub>2</sub>, OR, N(R)<sub>2</sub>, or optionally substituted phenyl, pyridyl, and pyrimidinyl.


21. (Currently amended) The compound of claim [(17)] 20, wherein each occurrence of ZR<sup>5</sup> is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, CF<sub>3</sub>, NH<sub>2</sub>, phenyl, benzyl, benzyloxy, OH, ~~methylene-dioxy~~ methylenedioxy, SO<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, CO<sub>2</sub>Me, phenoxy, O-pyridinyl, SO<sub>2</sub>phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, ~~aminophenyl~~, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, CF<sub>3</sub>-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.

22. (Currently amended) The compound of claim [(1,)] 18 having the formula IVa, wherein R<sup>x</sup> is hydrogen or optionally substituted C<sub>1-6</sub> aliphatic; m is 0, 1 or 2; and ZR<sup>1</sup> is Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, CF<sub>3</sub>, NH<sub>2</sub>, phenyl, benzyl, benzyloxy, OH, ~~methylene-dioxy~~ methylenedioxy, SO<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, CO<sub>2</sub>Me, phenoxy, O-pyridinyl, SO<sub>2</sub>phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, ~~aminophenyl~~, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, CF<sub>3</sub>-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.


23. (Original) The compound of claim 1, selected from one of the following compounds:



IVa-1




IVa-2




IVa-3


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-4




IVa-5




IVa-6




IVa-7




IVa-8




IVa-9




IVa-10




IVa-11




IVa-12



IVa-13




IVa-14




IVa-15


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-16




IVa-17




IVa-18




IVa-19




IVa-20




IVa-21




IVa-21




IVa-22




IVa-23




IVa-24



IVa-22




IVa-23




IVa-24


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-25




IVa-26




IVa-27




IVa-28




IVa-29




IVa-30




IVa-31




IVa-32




IVa-33




IVa-34



IVa-35














IVa-36




IVa-37


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-49




IVa-50




IVa-50




IVa-51




IVa-51




IVa-52




IVa-53



IVa-54















IVa-55




IVa-56


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

**IVa-57****IVa-58****IVa-59****IVa-60****IVa-61****IVa-61****IVa-62****IVa-63****IVa-63****IVa-64****IVa-65****IVa-66**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-67




IVa-68




IVa-69




IVa-70




IVa-71




IVa-71




IVa-71




IVa-72



IVb-1




IVb-2




IVb-3


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-4




IVb-5




IVb-6




IVb-7




IVb-8




IVb-9




IVb-10




IVb-11




IVb-12



IVb-13
















IVb-14




IVb-15

US 2006/0129123 A1  
NOV 9 2006  
USPTO


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

**IVb-16****IVb-17****IVb-18****IVb-19****IVb-20****IVb-21****IVb-21****IVb-22****IVb-23****IVb-24****IVb-22****IVb-23****IVb-24**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-25




IVb-26




IVb-27




IVb-28




IVb-29




IVb-30




IVb-31




IVb-32




IVb-33




IVb-34



IVb-35














IVb-36













IVb-37


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




Applicants: Randy S. Bethicl et al.  
Application No.: 10/700,936

**IVb-49****IVb-50****IVb-50****IVb-51****IVb-51****IVb-52****IVb-53****IVb-54****IVb-55****IVb-56**


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-57




IVb-58




IVb-59




IVb-60




IVb-61




IVb-61




IVb-62




IVb-62




IVb-63



IVb-64




IVb-65




IVb-66


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936




IVb-67




IVb-68




IVb-69




IVb-70




IVb-70



IVb-71



IVb-71



IVb-72.

or

24. (Original) A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. (Canceled)

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

26. (Previously presented) A method of inhibiting JAK-3 kinase activity in:

(a) a patient; or

(b) a biological sample;

which method comprises administering to said patient, or contacting said biological sample with a compound of claim 1 or a composition comprising said compound.

27. (Previously presented) A method of treating or lessening the severity of a disease or disorder selected from an immune response, an autoimmune disease, a neurodegenerative disease, or a solid or hematologic malignancy comprising administering to a subject in need thereof a compound of claim 1 or a composition comprising said compound.

28. (Original) The method of claim 27, wherein the disease or disorder is selected from an allergic or type I hypersensitivity reaction, asthma, transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, multiple sclerosis, Familial amyotrophic lateral sclerosis (FALS), leukemia, or lymphoma.

29. (Original) The method of claim 28, comprising the further step of administering to said patient an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder, wherein:

said additional therapeutic agent is appropriate for the disease being treated; and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.